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Summary
 
Antigens presented by class I major histocompatibility complex (MHC) molecules for recognition
by cytotoxic T lymphocytes consist of 8–10-amino-acid-long cytosolic peptides. It is not known
whether posttranslationally modified peptides are also presented by class I MHC molecules in
vivo. Many different posttranslational modifications occur on cytoplasmic proteins, including a
cytosolic O-
 
b
 
-linked glycosylation of serine and threonine residues with 
 
N
 
-acetylglucosamine
(GlcNAc). Using synthetic glycopeptides carrying the monosaccharide O-
 
b
 
-GlcNAc substitution
on serine residues, we have shown that glycopeptides bind efficiently to class I MHC molecules
and elicit a glycopeptide-specific cytotoxic T lymphocyte response in mice. In this study, we
provide evidence that peptides presented by human class I MHC molecules in vivo encompass
a small, significant amount of glycopeptides, constituting up to 0.1% of total peptide. Further-
more, we find that carbohydrate structures present on glycopeptides isolated from class I MHC
molecules are dominated by the cytosolic O-
 
b
 
-GlcNAc substitution, and synthetic peptides
carrying this substitution are efficiently transported by TAP (transporter associated with antigen
presentation) into the endoplasmic reticulum. Thus, in addition to unmodified peptides, post-
translationally modified cytosolic peptides carrying O-
 
b
 
-linked GlcNAc can be presented by
class I MHC molecules to the immune system.
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T
 
he majority of peptides presented by MHC molecules
for recognition by CD8
 
1 
 
CTLs are derived from cyto-
solic proteins that have been degraded in the cytosol before
transport via the transporter associated with antigen presen-
tation (TAP) into the endoplasmic reticulum (ER). Here,
the peptides assemble with “empty” class I MHC H chain
and 
 
b
 
2
 
-microglobulin (
 
b
 
2
 
m) into stable class I MHC–peptide
complexes, followed by their egress through the ER–Golgi
apparatus to the cell surface (1).
The nature of peptides presented naturally by classical
MHC molecules in normal or infected cells has been ex-
tensively studied, revealing features such as length restric-
tion and the presence of allele-specific amino acid motifs
corresponding to so-called peptide anchor residues (2). It
has also been clearly demonstrated that the great majority
of antigens presented by classical MHC molecules consist
of unmodified peptides. There is, however, a growing num-
ber of examples of class I MHC–restricted T cells recogniz-
ing products of posttranslational modifications in vivo, e.g.,
glycosylation (3), deglycosylation (4), or cysteinylation (5),
as well as class II MHC–restricted T cells recognizing pep-
tides modified by glycosylation (6, 7) or deamidation (8).
Previously, we have shown that class I MHC molecules
efficiently bind synthetic peptides carrying the naturally occur-
ring cytosolic type of O-
 
b
 
-GlcNAc (
 
N
 
-acetylglucosamine)
glycosylation. Furthermore, we have shown that such glyco-
peptides are immunogenic in mice, where they induce
classical class I MHC–restricted, 
 
a/b
 
-TCR
 
1
 
, glycopeptide-
specific CTL (9–11). No class I MHC reactivity has yet
been identified toward a defined, naturally processed glyco-
peptide. Although glycopeptides have been isolated from
class II MHC molecules (12), so far no glycopeptides have
been identified among peptides presented by class I MHC,
and it has not been investigated to what extent such modi-
fications persist during antigen presentation of cytosolic
peptide fragments in vivo. 
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Here, we present evidence that peptides carrying natural
cytosolic posttranslational modifications act as good sub-
strates for the TAP transporter. Furthermore, we demon-
strate that peptides presented naturally by human class I
MHC molecules contain a subset of glycopeptides with the
cytosolic O-
 
b
 
-GlcNAc monosaccharide glycosylation.
 
Materials and Methods
 
Peptides.
 
The following peptides and O-
 
b
 
-GlcNAc–substi-
tuted peptides were synthesized as previously described (9): wt-S
(FASGNYSAL), 417 (TVNKTERAY), 417-S (TVNKTESAY),
wt-G (FAS[O-
 
b
 
-GlcNAc]GNYSAL) and 417-G (TVNKTES
[O-
 
b
 
-GlcNAc]AY). The glycopeptides K1G, carrying an N-linked
monosaccharide, and K2G, carrying an O-
 
b
 
-linked monosaccha-
ride, have been described previously (9, 10). All peptides were
purified by reverse-phase (RP)-HPLC and characterized by mass
spectroscopy and nuclear magnetic resonance. Before use in the
TAP assay, some peptides were radiolabeled with Na-
 
125
 
I catalyzed
by chloramine-T.
 
Assay for TAP Transport of Peptides across the ER Membrane.
 
Assays for the TAP-mediated translocation of radiolabeled, post-
translationally modified peptides across the ER membrane of
human LCL721 cells were performed as described (13). T2 cells
were used to demonstrate the TAP dependence of transport.
Samples incubated in the absence of ATP were carried out as
controls for the ATP dependence of the transport. In competi-
tion assays, iodinated peptide 417 was mixed with competitor
peptide before addition to permeabilized cells. The substrate pep-
tide 417-G carrying O-
 
b
 
-GlcNAc monosaccharide is not itself a
ligand for Con A in the absence of an N-linked glycan, as seen
from the inability to recover 417-G by Con A–Sepharose in the
absence of ATP (see Fig. 1 B).
 
Immunoaffinity Isolation of Peptides from Human Class I MHC
Molecules.
 
MHC–peptide complexes were purified from 100 g
of normal human spleen (tissue type HLA-A3, -A30, -B7, -B8,
-Cw
 
*
 
0701, -Cw
 
*
 
0702; provided by Dr. M. Bunce, Churchill
Hospital, Oxford, England) lysed in 1% CHAPS (3-[(3-cholami-
dopropyl)-dimethylammonio]-1-propane-sulfonate)-containing buf-
fer as described (14). Affinity columns (Pharmacia HiTrap Pro-
tein A–Sepharose columns with 10 mg mAb/ml column volume)
were equilibrated with lysis buffer, and the lysate (10 g of tissue/ml
column volume) was passed through a Sepharose 4B precolumn,
then a column containing the irrelevant H-2D
 
b
 
–specific mAb 28-
14-8s, and finally a column conjugated with the anti–HLA class I
mAb W6/32. Each column was washed extensively with lysis
buffer, followed by 150 mM NaCl and 1.0 M NaCl (both with
20 mM Tris/HCl, pH 8.0) and then 20 mM Tris/HCl, pH 8.0,
before elution with 0.2 M acetic acid. Acetic acid was then added
to the eluate to a final concentration of 10%, and after 30 min on
ice, the eluate was filtered through prewashed 5,000-daltons cut-off
UFC4LCC00 ultrafiltration filters (Millipore Corp.), concen-
trated in a vacuum concentrator, and frozen at 
 
2
 
80
 
8
 
C. The
class I MHC–peptide complex affinity column eluates were ana-
lyzed for contaminating polypeptide on precast 10% NuPAGE
Bis-Tris SDS-PAGE (Novex). These gels can separate polypep-
tides in the 2.5–200-kD molecular mass range, when using a
2-(
 
N
 
-morpholino)ethane sulfonic acid containing SDS running
buffer (Novex). An aliquot of the column eluate corresponding to
50 
 
m
 
g of total protein was concentrated by vacuum centrifugation
and dissolved in PBS containing NuPAGE Sample Reducing
Agent and LDS Sample Buffer, according to the manufacturer’s
 
instructions (Novex), before heating and loading onto a 10 
 
3
 
10 cm precast NuPAGE gel in a Novex Xcell II Mini-Cell.
NuPAGE Antioxidant was added to the NuPAGE MES SDS
running buffer according to the manufacturer’s instructions. The
gel was run at 200 V for 35 min, after which it was stained in
Coomassie blue dye, destained O/N, and dried on paper using a
gel dryer. SeeBlue (Novex) prestained standard molecular mass
markers containing BSA (62 kD), glutamic dehydrogenase (49
kD), alcohol dehydrogenase (38 kD), carbonic anhydrase (28
kD), myoglobin (18 kD), lysozyme (14 kD), aprotinin (6 kD), and
insulin (B chain; 3 kD) were used for calibration.
 
 
Galactosyltransferase Labeling of Peptides.
 
Before labeling with [
 
3
 
H]
galactose (Gal) using bovine milk GlcNAc
 
b
 
1-4galactosyltrans-
ferase (15), the MHC-derived peptides were desalted by RP-HPLC,
lyophilized, and dissolved in water. Galactosyltransferase enzyme
(50 mU) was mixed with 20 
 
m
 
l labeling buffer (100 mM Hepes and
50 mM MnCl
 
2
 
, pH 7.3), 50 
 
m
 
l of peptide, 20 
 
m
 
l of 25 mM 5
 
9
 
-
AMP containing uridine 5
 
9
 
-diphosphate (UDP)-[
 
3
 
H]Gal (2.5 
 
m
 
Ci;
Amersham International), and water to a final volume of 200 
 
m
 
l.
The reaction proceeded for 90 min (37
 
8
 
C) before termination
with EDTA (0.1 M, pH 8.0).
 
Sensitivity of Labeled Peptides to N-glycosidase F or 
 
b
 
-elimination.
 
Equal aliquots of labeled peptide were mixed with 0.7 U pep-
tide–
 
N
 
-glycosidase F (Boehringer Mannheim) in sodium phos-
phate (pH 7.2) or 
 
b
 
-elimination buffer (0.1 M NaOH and 1 M
NaBH
 
4
 
, pH 13) (15, 16) and incubated at 37
 
8
 
C for 18 h. The
 
b
 
-elimination reaction was neutralized with 4 M acetic acid. Using
the synthetic peptides K1G (carrying an N-
 
b
 
-linked GlcNAc)
and K2G (carrying an O-
 
b
 
-linked GlcNAc), the 
 
b
 
-elimination
procedure was optimized such that it resulted in the complete re-
moval of [
 
3
 
H]Gal-labeled O-
 
b
 
-linked GlcNAc residues from
K2G while leaving all [
 
3
 
H]Gal-labeled N-linked GlcNAc resi-
dues on K1G intact. Ovalbumin was galactosyltransferase-labeled
with [
 
3
 
H]Gal and then shown to be efficiently deglycosylated by
 
N
 
-glycosidase F as a positive control for the procedure.
 
Analysis of Labeled Peptides by RP-HPLC.
 
The galactosyltrans-
ferase-labeled peptides were analyzed by RP-HPLC (3.9 mm 
 
3
 
15 cm, 300-Å Waters C-18 column) and an on-line radioactivity
monitor (Reeve Analytical Instruments). Buffer A: 0.1% (vol/vol,
unless otherwise stated) TFA in water; buffer B: 0.1% TFA in
acetonitrile. The gradient was 95:5 to 50:50 buffer A/buffer B in
45 min and 50:50 to 20:80 in 2 min (flow, 1 ml/min).
 
Analysis of the 
 
b
 
-Elimination Product by Size Exclusion Chroma-
tography.
 
After labeling of terminal GlcNAc residues with triti-
ated galactose, the peptides were RP-HPLC purified to separate
unincorporated, free label from peptide-bound [
 
3
 
H]Gal. The la-
beled peptides were analyzed by size exclusion chromatography
on a Bio-Gel P-2 column (10 
 
3
 
 350 mm; separation range, 100–
1,800 daltons) at a linear flow rate of 15.29 cm/h (200 
 
m
 
l/min)
PBS before and after 
 
b
 
-elimination. The column was calibrated
with GlcNAc (M
 
r
 
 
 
5 
 
221), chitobiose (GlcNAc
 
b
 
1-4GlcNAc; M
 
r
 
 
 
5
 
424), UDP-[
 
3
 
H]Gal (M
 
r
 
 
 
5 
 
569), K2G (M
 
r
 
 
 
5 
 
1125), and [
 
3
 
H]
Gal-K2G (M
 
r
 
 
 
5 
 
1287). The V
 
o
 
 and V
 
t
 
 volumes were determined
with BSA (M
 
r
 
 
 
5 
 
66.000) and 
 
51
 
Cr (M
 
r
 
 
 
5 
 
51.99), respectively.
 
Lectin-Affinity Chromatography of Class I MHC–derived Peptides.
 
Peptide–MHC complexes were affinity purified as described above
from a JestHom (expressing HLA-A
 
*
 
0201 and -B
 
*
 
2705; 5 
 
3
 
 10
 
10
 
cells) cell lysate using the mAb BB7.2 to extract HLA-A
 
*
 
0201–
peptide complexes, followed by W6/32 to extract HLA-B
 
*
 
2705
complexes. Subsequently, the isolated peptides were passed through
a series of 1-ml lectin–agarose affinity columns (Sigma Chemical
Co.) in the following sequence: (i) Con A, (ii) wheat germ agglu-
tinin (WGA), and (iii) and 
 
Arachis hypogea
 
 lectin (peanut lectin). 
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WGA beads were eluted with 1 M GlcNAc and the Con A beads
with 50 mM 
 
a
 
-methylmannoside. All three columns were washed
with 0.1 M glycine/HCl and equilibrated in PBS before the pep-
tide preparation was passed slowly through the columns. The col-
umns were washed with 200 ml PBS before elution with 50 mM
 
a
 
-methylmannoside (Con A), 1 M GlcNAc (WGA), or 0.1 M
glycine/HCl (peanut lectin).
 
Results and Discussion
 
In previous studies (9, 10), we have demonstrated how
peptides carrying the cytosolic type of O-linked GlcNAc
glycosylation of serine and threonine residues (17) consti-
tute a potential new group of antigenic epitopes. Our re-
cent X-ray crystallographic analysis of these class I MHC–
glycopeptide complexes show that the glycans are solvent
exposed and, though mobile, are orientated in such a way
as to permit specific contact with the TCR of glycopeptide-
specific CTL (11).
Natural presentation of such peptides by class I MHC in
vivo would require the proteolytic cleavage of O-
 
b
 
-GlcNAc–
containing glycopeptides from cytosolic glycoproteins, fol-
lowed by their transport into the ER, allowing binding to
class I MHC molecules. Fig. 1 shows that peptides carrying
the cytosolic O-
 
b
 
-GlcNAc modification are indeed sub-
strates for TAP-mediated transport across the ER mem-
brane. Fig. 1 A shows that the glycopeptide wt-G competed
about as efficiently as wt-S for translocation of 417 (IC
 
50
 
values, 12 and 8 
 
m
 
M for wt-S and wt-G, respectively). These
values remain well within the range of those obtained with
several natural immunodominant peptide epitopes (13). As-
says for direct translocation of glycopeptides by TAP were
carried out by adding radiolabeled peptides or glycopep-
tides, which contain an N-linked glycosylation sequon, to
streptolysin O–permeabilized cells. In the event of TAP-
mediated transport into the ER, these peptides will acquire
an N-linked glycan structure, thus allowing recovery with
 
Con A–Sepharose. Any difference in the amount of N-gly-
cosylated peptide between permeabilized TAP-competent
cells and TAP-deficient control cells (T2) is due to TAP-
mediated translocation of the peptide into ER. Peptide 417,
as well as 417-S, was very efficiently translocated by both
human (Fig. 1 B) and murine (data not shown) TAP, with
recoveries of 4–5% for LCL721, consistent with previously
published data (18). The glycosylated version of 417-S
(giving 417-G) was also translocated by TAP and resulted
in the recovery of 40–50% of the control peptide (Fig. 1 B).
These results are in accord with the finding that TAP al-
lows translocation of peptides with side chains much longer
than naturally occurring ones (19).
We next sought to determine to what extent O-GlcNAc–
containing glycopeptides were present amongst peptides
isolated from natural human class I MHC molecules affinity
purified from human spleen lysates. A widely used method
for the detection of O-b-GlcNAc on glycoproteins is based
on the enzymatic transfer of [3H]Gal from UDP-[3H]Gal onto
terminal GlcNAc residues in O-b-GlcNAc–containing pro-
teins, as well as N-linked carbohydrate structures, catalyzed
by galactosyltransferase (15).
Peptides presented by normal human spleen class I MHC
molecules were fractionated by RP-HPLC, and the major-
ity of peptides eluted in a typical broad interval correspond-
ing to 10–35% buffer B. Numerous well defined individual
peaks were clearly distinguishable above a bell-shaped UV
trace of heterogeneously eluting peptide material. SDS-PAGE
analysis of the MHC–peptide preparation demonstrated the
absence of contaminating low molecular weight proteins,
which might separate with the peptides during the ultrafil-
tration (Fig. 2, insert). An identical aliquot of the class I
MHC–derived peptides was then subjected to galactosyl-
transferase-mediated labeling with [3H]Gal. Fig. 2 B shows
that radioactively labeled peptide material eluted between
10 and 35 min and was dominated by two to three major
peaks at 20% buffer B, while also containing many minor
labeled species. This result suggests that a small fraction of
peptides isolated from natural class I MHC molecules was
able to act as substrate for the GlcNAc-specific galactosyl-
transferase, strongly indicating that the pool of peptides
eluted from MHC class I contain a subset of peptides with
covalently linked terminal GlcNAc structures. Importantly,
similar glycopeptides were not present in the negative control
precolumn extract, derived using an irrelevant Ab (28-14-8s,
H-2Db-specific; results not shown). This strongly supports
the interpretation that the labeled glycopeptides have in-
deed been presented by class I MHC molecules. Based on
comparisons with positive control O-b-GlcNAc–contain-
ing glycopeptides, we estimate that the amount of labeled
peptide corresponds to 0.1% of peptides presented by class I
MHC being O-glycosylated.
To characterize the carbohydrate structures and their
linkages on peptides from class I MHC, aliquots of the
[3H]Gal-labeled peptides were treated with N-glycosidase
F or weak alkali (b-elimination). N-glycosidase F cleaves
N-linked carbohydrate structures, whereas only O-b-linked
carbohydrate structures are susceptible to b-elimination (16).
Figure 1. TAP-mediated transport of posttranslationally modified pep-
tides. (A) Competition of peptide 417 translocation by glycopeptide wt-G
(s), unmodified peptide wt-S (n), or index peptide 417 (m). The amount
of iodinated index peptide is expressed as a fraction of the amount recov-
ered in the absence of competitor. (B) Direct translocation of iodinated gly-
copeptides was analyzed by comparing translocation of peptide 417 with a
serine-substituted analogue (417-S), as well as an O-GlcNAc–glycosylated
(417-G) version thereof. The results are the amounts of translocated peptide
recovered expressed as a fraction of total input peptide.148 Natural Presentation of Glycopeptides by Class I MHC
Fig. 2 C shows that the amount of [3H]Gal-labeled glyco-
peptides recovered after b-elimination was significantly
reduced, whereas the labeled peptides were not sensitive to
treatment with N-glycosidase F digestion (data not shown).
This indicates that the majority of MHC-derived peptides
that could be labeled by the galactosyltransferase contained
O-b-linked GlcNAc residues.
Next, the radioactively labeled glycans were analyzed by
size exclusion chromatography. As seen in Fig. 3 A, pep-
tides isolated from human class I MHC and labeled with
[3H]Gal using galactosyltransferase eluted in a broad peak at
z40 min. This corresponds to the elution time of [3H]Gal-
labeled K2G (Fig. 3 A, arrows), a prototype synthetic class I
MHC–restricted nine–amino acid-long glycopeptide car-
rying one O-b-linked GlcNAc residue (10). In addition,
a late-eluting peak, equivalent to the size of [3H]Gal, was
found at 90 min. As the b-elimination reaction reduces any
free reducing sugar to alditol, the carbohydrate reaction by-
product would be the alcohol form of the disaccharide [3H]
Galb1-4GlcNAc if peptides from MHC class I originally
carried O-b-linked GlcNAc monosaccharide. Accordingly,
after b-elimination, the elution by size exclusion chroma-
tography of the glycan product from the [3H]Gal-labeled
class I MHC–derived peptides corresponded accurately with
the elution time of [3H]Gal-GlcNAcitol (Fig. 3 B), similar to
the elution time of the O-GlcNAc–containing positive con-
trol peptide K2G b-elimination product (Fig. 3 C). More
than 95% of the [3H]Gal-labeled class I MHC–derived pep-
tides were sensitive to b-elimination, whereas ,1% of the la-
bel incorporated into the N-linked glycan control peptide
K1G was sensitive to the b-elimination procedure (data not
shown), strongly supporting that the glycan structures present
on a subset of peptides from human spleen class I MHC are
dominated by the cytosolic type of O-b-linked GlcNAc gly-
cosylation. We did not find any evidence for the presence of
glycan structures other than the O-b-GlcNAc modification
among peptides isolated from class I MHC molecules.
In a separate attempt to demonstrate that O-b-GlcNAc–
modified peptides were specifically bound to MHC mole-
cules, peptides eluted from HLA-A*0201 that had been af-
Figure 2. RP-HPLC chromatogram of peptides extracted from human
spleen class I MHC molecules before labeling with [3H]Gal. (A) The
boxed inset is an SDS-PAGE analysis of the MHC–peptide preparation
with molecular mass standards on the left. (B) The corresponding radioac-
tivity trace after galactosyltransferase labeling of these peptides with
[3H]Gal using bovine milk galactosyltransferase. C illustrates the sensitiv-
ity of [3H]Gal-labeled peptides to b-elimination. An aliquot of labeled
peptide identical to that in B was subjected to b-elimination and analyzed
by RP-HPLC.
Figure 3. The b-elimination glycan product of peptides labeled with
[3H]Gal was subjected to size exclusion chromatography on a Bio-Gel P-2
column. This column separates mono- and disaccharides efficiently and
distinguishes between GlcNAcb1-4GlcNAc and Galb1-4GlcNAc. Ar-
rows at the top indicate the elution of compounds used to calibrate the
column. (A) Elution of [3H]Gal-labeled class I MHC–derived peptides.
(B) Elution of the glycan b-elimination product of [3H]Gal-labeled class I
MHC–derived peptides. (C) Elution of the glycan b-elimination product
of [3H]Gal-labeled positive control peptide K2G.149 Haurum et al. Brief Definitive Report
finity purified from 1010 JestHom cells were passed through
a series of lectin affinity columns in the following order:
(i) Con A (specific for high-mannose structures in N-glyco-
sylated proteins), (ii) WGA (specific for terminal GlcNAc
residues), and (iii) and Arachis hypogea lectin (specific for sac-
charide structures containing terminal N-acetylgalactosamine
(GalNAc) residues, as they are found in the mucin-type
O-linked glycosylation). The majority (99%) passed through
the affinity columns (data not shown). The WGA column
retained z1% of the peptides (Fig. 4 B), supporting the no-
tion that O-b-GlcNAc–modified peptides are represented
among natural HLA-A*0201 ligands. Markedly less pep-
tide-like material was retained by the Con A column (Fig.
4 A), which, being first in the series, is likely to contain any
nonspecific binding material. Almost no peptide was re-
tained by the peanut lectin column (data not shown). Sim-
ilar overall results were obtained for the HLA-B*2705–
derived peptides, although the fraction of peptide retained
by the lectin columns was significantly lower (not shown),
possibly reflecting an incompatibility between the sequence
requirement for peptide binding to HLA-B*2705 and the
specificity requirements of the O-b-GlcNAc transferase re-
sponsible for O-b-GlcNAc glycosylation.
The cytosolic O-b-GlcNAc modification is known to be
dynamically regulated and changes reciprocally with phos-
phorylation in response to cellular activation (17). This study
shows that steady-state, low-level presentation by class I MHC
molecules of glycopeptides carrying the cytosolic type of
O-b-GlcNAc modification occurs in normal cells, and it is
possible that regulatory changes in O-GlcNAc glycosylation
during malignancy could result in the presentation of novel
glycopeptides for recognition by CTL. In addition, presen-
tation of O-b-GlcNAc–modified proteins may be relevant
during infection, as examples of cytosolic O-b-GlcNAc–
modified proteins have been identified from human cyto-
megalovirus (20), adenovirus (21), trypanosomes (22), schisto-
somes (23), leishmania (24), and malaria (25). With improved
techniques to detect glycopeptides among complex mixtures
of peptides eluted from class I MHC molecules isolated from
normal, infected, and malignant cells, it may soon be possible
to identify glycoprotein antigens that can be processed to
yield glycopeptide epitopes for class I MHC–restricted anti-
gen presentation.
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